Management of hydroxyurea resistant or intolerant polycythemia vera

References

• Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94(1):133–143.
   PubMed Web of Science ®Google Scholar
• Chievitz E, Thiede T. Complications and causes of death in polycythaemia vera. Acta Med Scand. 1962;172(5):513–523.
   PubMedGoogle Scholar
• Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R, Kutti J, et al.; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–124.
   PubMed Web of Science ®Google Scholar
• Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–1069.
   PubMed Web of Science ®Google Scholar
• McMullin MF, Harrison CN, Ali S, et al.; BSH Committee. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol. 2019;184(2):176–191.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, et al.; the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016;172(5):786–793.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363–1369.
   PubMed Web of Science ®Google Scholar
• Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148(6):961–963.
   PubMed Web of Science ®Google Scholar
• Spivak JL, Hasselbalch H. Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther. 2011;11(3):403–414.
   PubMed Web of Science ®Google Scholar
• Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood J Am Soc Hematol. 2009;113(20):4829–4833.
   Google Scholar
• Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778–4781.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, Holmström MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol. 2019;41(1):5–19.
   PubMed Web of Science ®Google Scholar
• Kiladjian J-J, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α–2a. Blood. 2006;108(6):2037–2040.
   PubMed Web of Science ®Google Scholar
• Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202(1):8–32.
   PubMedGoogle Scholar
• Krause CD, Pestka S. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol Ther. 2005;106(3):299–346.
   PubMed Web of Science ®Google Scholar
• Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375–386.
   PubMed Web of Science ®Google Scholar
• Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol. 2004;41(2 Suppl 3):15–17.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762–1769.
   PubMed Web of Science ®Google Scholar
• Kiladjian J-J, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065–3072.
   PubMed Web of Science ®Google Scholar
• Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017;4(4):e165–e175.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Kosiorek HE, Prchal JT, et al. Results of the myeloproliferative neoplasms – Research Consortium (MPN-RC) 112 randomized trial of pegylated interferon Alfa-2a (PEG) versus Hydroxyurea (HU) therapy for the treatment of high risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). Blood. 2018;132(Suppl 1):577–577.
   PubMedGoogle Scholar
• Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134(18):1498–1509.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Klade C, Georgiev P, et al. Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera patients. Washington, DC: American Society of Hematology; 2016.
   Google Scholar
• Gisslinger H, Klade C, Georgiev P, PROUD-PV Study Group, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196–e208.
   PubMed Web of Science ®Google Scholar
• Gisslinger HK, Georgiev C, Krochmalczyk P, et al. Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension. 634. 62nd ASH Annual Meeting and Exposition; December 6th, 2020; Virtual: American Society of Hematology; 2020.
   Google Scholar
• Barbui TV, Alessandro M, De Stefano V, et al. Phase II randomized clinical trial comparing ropeginterferon versus phlebotomy in low-risk patients with polycythemia vera. Results of the pre-planned interim analysis. Late breaking oral session. 25th European Haematology Association annual congress; June 14th, 2020; Virtual; 2020.
   Google Scholar
• Sonbol MB, Firwana B, Zarzour A, et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol. 2013;4(1):15–35.
   PubMedGoogle Scholar
• Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol. 1995;13(1):369–398.
   PubMedGoogle Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117–1127.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513–520.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016;101(7):821–829.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017;18(1):88–99.
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Saydam G, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol. 2018;97(9):1591–1600.
   PubMed Web of Science ®Google Scholar
• Foltz L, Pica G-M, Zerazhi H, et al. Updated results from an open-label, multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b study of Ruxolitinib (RUX) in patients (Pts) with Polycythemia Vera (PV) who were Hydroxyurea (HU) resistant or intolerant and for whom no alternative treatment (Tx) was available. Blood. 2018;132(Suppl 1):1774.
   Google Scholar
• Harrison C, McMullin M, Panchal A, editors. Ruxolitinib compared with best available therapy for polycythemia vera patients resistant or intolerant to hydroxycarbamide in MAJIC – an investigator-led randomized trial. Poster presented at 23rd Annual Congress of the European Hematology Association; 2018.
   Google Scholar
• Mesa R, Vannucchi AM, Yacoub A, et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).Br J Haematol. 2017;176(1):76–85.
   PubMed Web of Science ®Google Scholar
• Sørensen AL, Mikkelsen SU, Knudsen TA, et al. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematology. 2020;105(9):2262–2272.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Lu M, Kosiorek H, et al. Oral idasanutlin in patients with polycythemia vera. Blood J Am Soc Hematol. 2019;134(6):525–533.
   Google Scholar
• Mascarenhas JH, Anders B, Burbury D, et al. Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study. Oral presented at: 634. 62nd ASH Annual Meeting and Exposition; December 6, 2020; Virtual: American Society of Haematology; 2020.
   Google Scholar
• Andersen CL, McMullin MF, Ejerblad E, et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2013;162(4):498–508.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Iurlo A, Vannucchi AM, et al. Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Leukemia. 2020;34(8):2234–2237.
   PubMed Web of Science ®Google Scholar
• Ginzburg YZ, Feola M, Zimran E, et al. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32(10):2105–2116.
   PubMed Web of Science ®Google Scholar
• Casu C, Oikonomidou PR, Chen H, et al. Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera. Blood J Am Soc Hematol. 2016;128(2):265–276.
   Google Scholar
• Kremyanskaya MG, Kuykendall Y, Yacoub A, et al. PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients. 634. 62nd ASH annual meeting and exposition; December 6th, 2020; Virtual: American Society of Haematology; 2020.
   Google Scholar
• Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418–5424.
   PubMed Web of Science ®Google Scholar